| 1 |
Chen M, Cui Y, Liu C, Tong X, Wang M, Wu C, Liu Y, Zhao Y, Chen X. Characteristics of the microbiome in lung adenocarcinoma tissue from patients in Kunming city of southwestern China. Environ Sci Pollut Res Int 2023. [PMID: 36787077 DOI: 10.1007/s11356-023-25528-1] [Reference Citation Analysis]
|
| 2 |
Hajjo R, Sabbah DA, Al Bawab AQ. Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers. Diagnostics 2022;12:1742. [DOI: 10.3390/diagnostics12071742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Wu M, Bai J, Ma C, Wei J, Du X. The Role of Gut Microbiota in Tumor Immunotherapy. J Immunol Res 2021;2021:5061570. [PMID: 34485534 DOI: 10.1155/2021/5061570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G. Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Front Immunol 2021;12:643255. [PMID: 34054810 DOI: 10.3389/fimmu.2021.643255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Wang L, Gu W, Ni H. Construction of a prognostic value model in papillary renal cell carcinoma by immune-related genes. Medicine (Baltimore) 2021;100:e24903. [PMID: 33761648 DOI: 10.1097/MD.0000000000024903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 6 |
Zuo ZT, Ma Y, Sun Y, Bai CQ, Ling CH, Yuan FL. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol 2021;182:53-64. [PMID: 33080611 DOI: 10.1159/000508330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 7 |
Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, Chang C, El-Kafrawy SA, Osman M, Zitvogel L, Galle PR, Locatelli F, Gorman E, Cordon-Cardo C, O'Kane C, McAuley D, Maeurer M. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis. 2020;96:431-439. [PMID: 32425638 DOI: 10.1016/j.ijid.2020.05.040] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
|
